“We have considerable momentum heading into the end of the year. We see tremendous potential for ozureprubart in large IgE-driven indications such as food allergy and CSU, and our recent financing gives us additional capital to advance our programs,” said Brian Wong, President and CEO of RAPT. “Looking ahead, we plan to report topline results from Jeyou’s Phase 2 trial of ozureprubart in asthma and to provide additional details from the recently reported Phase 2 clinical trial in CSU at a medical meeting next year. We also plan to meet with the FDA and other regulatory agencies to discuss the registrational pathway in CSU.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics price target raised to $72 from $48 at Wells Fargo
- Rapt Therapeutics price target raised to $72 from $27 at H.C. Wainwright
- Clear Street positive on Rapt Therapeutics into food allergy study
- Rapt Therapeutics initiates prestIgE Phase 2b trial
- Rapt Therapeutics initiated with a Buy at Guggenheim